ASCO/EHA/ICML 2023 – Paolo Strati
Paolo Strati overviews how patient outcomes can be optimized with current therapies in relapsed or refractory diffuse large B-cell lymphoma in later lines and outlines which innovative approaches might become available in the long run for the treatment of R/R DLBCL. Finally, he explains what can be achieved today in patients with follicular lymphoma and high tumor burden and depicts his personal highlights from this year’s EHA congress.
Here is the full ASCO/EHA/ICML 2023 report.
More posts
DLBCL: treatment of elderly patients and relapsed disease
DLBCL: treatment of elderly patients and relapsed disease POLAR BEAR: novel regimen fr
Waldenström macroglobulinemia: findings from ASPEN and BRUIN
Waldenström macroglobulinemia: findings from ASPEN and BRUIN ASPEN: HRQoL for zanubrut
Outcome improvements in relapsed and untreated marginal zone lymphoma
Outcome improvements in relapsed and untreated marginal zone lymphoma Final analysis o
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors
Follicular lymphoma: study results with bispecific antibodies and BTK inhibitors Mosun
Current insights into BTK inhibition and other targeted approaches in CLL
Current insights into BTK inhibition and other targeted approaches in CLL Treatment-na
Preface – ASCO/EHA/ICML 2023
Preface – ASCO/EHA/ICML 2023 © Dirk Gillissen – Arnon P. Kater, MD, PhD, Department o